Vetr cut shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a hold rating to a sell rating in a research note released on Monday, July 24th. The brokerage currently has $28.85 target price on the biopharmaceutical company’s stock.
Several other brokerages have also recently commented on JUNO. BidaskClub upgraded shares of Juno Therapeutics from a buy rating to a strong-buy rating in a research report on Tuesday, June 27th. Zacks Investment Research upgraded shares of Juno Therapeutics from a strong sell rating to a hold rating in a research report on Wednesday, July 5th. FBR & Co lowered their price objective on shares of Juno Therapeutics from $30.00 to $29.00 and set a mkt perform rating for the company in a research report on Friday, May 5th. Wedbush reiterated a neutral rating and set a $24.00 price objective on shares of Juno Therapeutics in a research report on Friday, May 5th. Finally, Leerink Swann reiterated an outperform rating and set a $34.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $30.81.
Shares of Juno Therapeutics (JUNO) traded up 0.10% during mid-day trading on Monday, reaching $29.10. 824,705 shares of the company’s stock traded hands. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04. The stock’s market cap is $3.03 billion. The firm has a 50 day moving average price of $27.95 and a 200-day moving average price of $24.15.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million during the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative net margin of 288.66% and a negative return on equity of 24.57%. Juno Therapeutics’s quarterly revenue was down 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. On average, analysts predict that Juno Therapeutics will post ($2.98) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/08/04/juno-therapeutics-inc-nasdaqjuno-downgraded-by-vetr-inc-to-sell-updated.html.
In other Juno Therapeutics news, Director Anthony B. Evnin bought 9,000 shares of Juno Therapeutics stock in a transaction on Tuesday, June 20th. The shares were purchased at an average cost of $24.40 per share, with a total value of $219,600.00. Following the acquisition, the director now directly owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,041,500 shares of company stock worth $217,230,360 over the last three months. Insiders own 15.26% of the company’s stock.
Several large investors have recently bought and sold shares of JUNO. Bank of New York Mellon Corp raised its stake in Juno Therapeutics by 7.3% in the second quarter. Bank of New York Mellon Corp now owns 281,858 shares of the biopharmaceutical company’s stock worth $8,425,000 after buying an additional 19,057 shares in the last quarter. State of Wisconsin Investment Board raised its stake in Juno Therapeutics by 1.7% in the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 210 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in Juno Therapeutics by 70.1% in the second quarter. Canada Pension Plan Investment Board now owns 160,600 shares of the biopharmaceutical company’s stock worth $4,800,000 after buying an additional 66,200 shares in the last quarter. Pictet Asset Management Ltd. raised its stake in Juno Therapeutics by 20.5% in the second quarter. Pictet Asset Management Ltd. now owns 463,435 shares of the biopharmaceutical company’s stock worth $10,766,000 after buying an additional 78,690 shares in the last quarter. Finally, CAPROCK Group Inc. purchased a new stake in Juno Therapeutics during the second quarter worth approximately $299,000. 64.51% of the stock is currently owned by institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
